Bupropion hydrobromide

氢溴酸安非他酮

Report date: 2026/03/30 17:02:26

Base Information

Drug NameBupropion hydrobromide
Drug Alias NameBupropione, Bromhydrate deBupropioni HydrobromidumAplenzinBVF-033
ClassificationSmall molecules
Mechanisms of ActionDopamine transporter antagonistsNorepinephrine transporter inhibitorsAdrenergic receptors antagonists +[4] 
TargetsNorepinephrine transporterDopamine transporterAdrenergic receptors
Therapy Area/IndicationsSchizophreniaSchizophrenia Spectrum and Other Psychotic DisordersAttention Deficit Disorder with Hyperactivity +[26] 
Global Approved IndicationsDepressive Disorder, Major
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2008/04/23
Country/TerritoryCzechiaBelgiumCanada +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesValeant
China Registration ClassN/A

Develop Information

Active CompaniesBausch Health Us LlcThe University Of Kansas Medical Center
Inactive CompaniesCanadian Institutes Of Health Research (Cihr)University Of California San FranciscoGlaxosmithkline Plc +[20] 
Active IndicationsSeasonal Affective DisorderDepressive Disorder, MajorSmoking Cessation
Inactive IndicationsSchizophreniaSchizophrenia Spectrum and Other Psychotic DisordersAttention Deficit Disorder with Hyperactivity +[23] 

Other Information

ATC CodeN06AX12
Related LinksWikipediaDrugBankKEGG